Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
87.19B
Market cap87.19B
Price-Earnings ratio
-30.35
Price-Earnings ratio-30.35
Dividend yield
—
Dividend yield—
Average volume
10.59M
Average volume10.59M
High today
$222.96
High today$222.96
Low today
$212.50
Low today$212.50
Open price
$216.67
Open price$216.67
Volume
7.02M
Volume7.02M
52 Week high
$280.80
52 Week high$280.80
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 87.19B, Moderna(MRNA) trades at $213.30. The stock has a price-to-earnings ratio of -30.35.

On 2026-11-16, Moderna(MRNA) stock traded between a low of $212.50 and a high of $222.96. Shares are currently priced at $213.30, which is +0.4% above the low and -4.3% below the high.

Moderna(MRNA) shares are trading with a volume of 7.02M, against a daily average of 10.59M.

During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $280.80 at its peak.

During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $280.80 at its peak.

MRNA News

TipRanks 2h
Moderna Amends Credit Agreement, Extends Loan Maturities

An announcement from Moderna ( (MRNA) ) is now available. On November 9, 2026, Moderna entered into an amendment to its credit agreement with Ares Capital Corp...

The Motley Fool 4h
Is Moderna's Cancer Vaccine a Game Changer for the Stock?

The market has been wildly excited about Moderna (MRNA -3.63%) this year, as it has soared more than 600% since January. The stock has been red hot on news that...

Is Moderna's Cancer Vaccine a Game Changer for the Stock?
24/7 Wall St. 10h
Moderna Is Up Over 600% This Year. Here's What Jim Cramer Learned in His Exclusive

Investing Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive By Chris Lange 𝕏 f ⧉ Quick Read Moderna (MRNA) soared from $63 to a...

Moderna Is Up Over 600% This Year. Here's What Jim Cramer Learned in His Exclusive

Analyst ratings

59%

of 27 ratings
Buy
18.5%
Hold
59.3%
Sell
22.2%

More MRNA News

The Motley Fool 2d
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

Investors are weighing high-growth pharmaceutical specialists against established platform companies. Choosing between Axsome Therapeutics (AXSM -1.86%) and Mod...

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
TipRanks 3d
Moderna Chief Legal Officer Announces Retirement Agreement

Moderna ( (MRNA) ) just unveiled an update. On Nov. 13, 2026, Moderna entered a transitional services and retirement agreement with Chief Legal Officer Shannon...

Simply Wall St 3d
Moderna Lands New Vaccine Data Win And Global Index Inclusion

Moderna (NasdaqGS:MRNA) reported peer reviewed real world data showing its mNEXSPIKE COVID 19 vaccine reduced medically attended COVID 19 in adults aged 65+. T...

Moderna Lands New Vaccine Data Win And Global Index Inclusion
TipRanks 3d
Moderna Maintains Hold Rating as Intismeran Execution Risks Offset Long-Term Oncology Potential; $260 Price Target Unchanged

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Moderna, with a price target of $260.00. Alec Strana...

TipRanks 3d
Moderna Advances Updated mRNA Flu Vaccine Study as Investors Watch Pipeline Progress

Moderna (MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna’s Phase 3b/4 study, titled A Phase 3b/4 Study to Assess the Immunog...

Zacks 4d
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

Moderna (MRNA Quick QuoteMRNA - Free Report) outlined its next phase of growth at its 2026 Analyst Day, highlighting oncology as a key long-term growth op...

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Barron's 4d
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.

BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy. BioNTech has multiple catalysts that could generate a rally of 35% for the stock....

BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.